Page last updated: 2024-12-05

phenetidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenetidine refers to a group of organic compounds that are derivatives of aniline. These compounds are characterized by an ethoxy group (-OCH2CH3) attached to the aromatic ring. There are two main isomers of phenetidine: o-phenetidine (2-ethoxyaniline) and p-phenetidine (4-ethoxyaniline).

Phenetidines have been historically used in the synthesis of various pharmaceuticals, including antipyretics, analgesics, and antiseptics. For example, phenacetin (acetophenetidin), a well-known analgesic, was once widely used but has been largely discontinued due to its potential for adverse effects.

The synthesis of phenetidines typically involves the reaction of aniline with ethyl bromide or ethyl chloride in the presence of a strong base. The reaction proceeds via an SN2 mechanism, where the ethoxy group replaces a hydrogen atom on the aromatic ring.

The effects of phenetidines can vary depending on the specific isomer and the dosage. Some phenetidines exhibit analgesic and antipyretic properties, while others may have toxic effects. The study of phenetidines has been driven by their historical use in medicine, their potential for pharmacological activity, and their role in understanding the structure-activity relationships of aromatic compounds. However, concerns about their safety have led to the discontinuation of many phenetidine-containing drugs.'

Phenetidine: Used in the manufacture of acetophenetidin. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-ethoxyaniline : An aromatic ether that is aniline in which the hydrogen at position 4 is replaced by an ethoxy group. It is a hydrolysis metabolite of phenacetin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7203
CHEMBL ID1525301
CHEBI ID190954
SCHEMBL ID15704
MeSH IDM0016507
PubMed CID9076
CHEMBL ID250969
CHEBI ID85505
SCHEMBL ID15703
MeSH IDM0016507

Synonyms (148)

Synonym
BIDD:GT0222
BB 0259298
1321-31-9
benzenamine, ar-ethoxy-
ethoxyaniline
nsc-9818
94-70-2
2-aminophenetole
nsc9818
o-phenetidine
o-aminophenetole
benzenamine, 2-ethoxy-
2-ethoxyaniline
o-ethoxyaniline
OPREA1_234512
aminophenetole
inchi=1/c8h11no/c1-2-10-8-6-4-3-5-7(8)9/h3-6h,2,9h2,1h
NCGC00091388-01
ccris 4697
nsc 9818
ai3-09043
2-ethoxybenzenamine
1-amino-2-ethoxybenzene
einecs 202-356-4
brn 0637069
2-ethoxyphenylamine
o-phenetidine, >=97.0% (gc)
smr001307334
MLS002303053 ,
AKOS000102651
P0089
CHEBI:190954
NCGC00091388-02
HMS3039A17
dtxsid5025863 ,
NCGC00258556-01
tox21_201003
dtxcid105863
cas-94-70-2
2-phenetidine
STL169148
unii-i76155s2aa
ec 202-356-4
4-13-00-00807 (beilstein handbook reference)
i76155s2aa ,
phenetidine, o-
o-phenetidine [mi]
2-ethoxy aniline
ortho-phenetidine
SCHEMBL15704
cid_7203
bdbm74412
un 2311
W-100189
CHEMBL1525301
F2190-0443
mfcd00007689
o-phenetidin
CS-W004149
FS-4093
AMY38133
Q27280535
o-phenitidine
2-ethoxy-aniline
EN300-20503
F87373
Z104478442
BIDD:GT0388
BB 0241911
phenethidine
benzenamine, 4-ethoxy-
4-aminophenetole
156-43-4
nsc-3116
p-ethoxyaniline
aniline, p-ethoxy-
nsc3116
4-ethoxyaniline
p-phenetidin
wln: zr do2
p-phenetidine
p-aminophenetole
1-amino-4-ethoxybenzene
phenetidine
inchi=1/c8h11no/c1-2-10-8-5-3-7(9)4-6-8/h3-6h,2,9h2,1h
4-ethoxy-aniline
NCGC00091785-01
ethyl p-aminophenol
brn 0606666
p-aminofenetol [czech]
nsc 3116
cp 5685
p-fenetidin [czech]
einecs 205-855-5
4-aminoethoxybenzene
4-ethoxybenzenamine
ai3-09042
ccris 2878
4-ethoxyaniline, 98%
STK397546
CHEMBL250969
chebi:85505 ,
AKOS000100572
smr001252219
MLS002454444
P0090
NCGC00091785-02
HMS3041D03
NCGC00257138-01
tox21_303334
cas-156-43-4
dtxcid505864
dtxsid0025864 ,
NCGC00259495-01
tox21_201946
(4-ethoxyphenyl)-amine
4-phenetidine
4-13-00-01017 (beilstein handbook reference)
9tsl224zse ,
unii-9tsl224zse
p-fenetidin
ec 205-855-5
p-aminofenetol
4-ethoxyanilin
(4-ethoxyphenyl) amine
phenetylamine
SCHEMBL15703
p-ethoxyphenylamine
p-phenetidine [mi]
phenetidine, p-
p-phenetidine [inci]
Q-200467
4-aminophenyl ethyl ether
p-aminophenyl ethyl ether
p-aminoethoxybenzene
para-aminoethoxybenzene
un 2311 (salt/mix)
4-ethoxybenzeneamine
F2190-0444
mfcd00007865
Q27158608
VS-0323
STR01492
AMY38132
E78819
EN300-17982
Z57127438
PD055436
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
substituted aniline
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
substituted aniline
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase I - Functionalization of compounds69175

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency54.09510.006038.004119,952.5996AID1159521
AR proteinHomo sapiens (human)Potency22.96870.000221.22318,912.5098AID1259243; AID1259381
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency16.16450.001022.650876.6163AID1224838; AID1224839
retinoid X nuclear receptor alphaHomo sapiens (human)Potency3.86240.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.03310.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.41990.000229.305416,493.5996AID1259244
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.70790.707936.904389.1251AID504333
IDH1Homo sapiens (human)Potency5.17350.005210.865235.4813AID686970
aryl hydrocarbon receptorHomo sapiens (human)Potency58.58270.000723.06741,258.9301AID743085; AID743122
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency12.96740.004611.374133.4983AID624296; AID624297
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency30.41990.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency30.41990.001551.739315,848.9004AID1259244
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency70.79460.004023.8416100.0000AID485290
LuciferasePhotinus pyralis (common eastern firefly)Potency79.64070.007215.758889.3584AID1224835
AR proteinHomo sapiens (human)Potency40.10340.000221.22318,912.5098AID743035; AID743063
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency58.83540.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency21.73410.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency14.54170.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency49.18230.001530.607315,848.9004AID1224848; AID1224849; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.58420.000229.305416,493.5996AID743075; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency50.11870.001024.504861.6448AID588535
aryl hydrocarbon receptorHomo sapiens (human)Potency36.40520.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency38.64920.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency100.96100.039147.5451146.8240AID1224845; AID1224896
importin subunit beta-1 isoform 1Homo sapiens (human)Potency6.51315.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency6.51315.804836.130665.1308AID540253
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency52.15870.000627.21521,122.0200AID651741; AID743202; AID743219
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency6.51315.804816.996225.9290AID540253
VprHuman immunodeficiency virus 1Potency12.58931.584919.626463.0957AID651644
Guanine nucleotide-binding protein GHomo sapiens (human)Potency25.11891.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ORF73Human gammaherpesvirus 8EC50 (µMol)75.00000.06008.134632.1400AID435023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID307625Partition coefficient, log P of the compound
AID1145375Antimicrobial activity against Mycobacterium tuberculosis1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Molecular connectivity. 6. Examination of the parabolic relationship between molecular connectivity and biological activity.
AID307626Solubility in water
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (69.57)18.7374
1990's4 (5.80)18.2507
2000's6 (8.70)29.6817
2010's8 (11.59)24.3611
2020's3 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.41 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index55.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (1.37%)5.53%
Reviews0 (0.00%)6.00%
Reviews2 (2.74%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (1.37%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other69 (94.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]